retatrutide phase 3 results october 2025 just delivered the first top-line for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 Retatrutide Phase 3 Results: TRIUMPH-1

It presents as a purple or blue discoloration that gradually fades through green and yellow over 7 to 14 days

Additionally, neither male (Supplemental Figure 1, KP) nor female (Supplemental Figure 1, QV) heterozygous Bbs5 +/ mice displayed any discernable phenotypic changes compared with WT controls

Residual fatigue at this stage usually points to an unaddressed nutritional deficiency, inadequate sleep quality, or excessive caloric restriction

They're going through puberty

Common examples: J3490 Unclassified drugs (used when no permanent code exists) J3590 Unclassified biologics J1817 Insulin (some combo therapies) Many GLP-1 drugs are processed under a pharmacy benefit rather than a medical benefit

Data analysis was performed using R (version 4.0.3) (R Core Team, 2020) via RStudio (version 1.3.1093) (RStudio Team, 2020)